BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,996 | -86.5% | 14,978 | +39.5% | 0.00% | – |
Q2 2023 | $22,122 | -38.6% | 10,739 | -1.8% | 0.00% | – |
Q1 2023 | $36,008 | +125.0% | 10,939 | -0.9% | 0.00% | – |
Q4 2022 | $16,000 | -66.7% | 11,039 | +1.8% | 0.00% | – |
Q3 2022 | $48,000 | +54.8% | 10,839 | 0.0% | 0.00% | – |
Q2 2022 | $31,000 | -97.7% | 10,839 | 0.0% | 0.00% | -100.0% |
Q1 2022 | $1,329,000 | +3222.5% | 10,839 | +7.1% | 0.00% | – |
Q4 2021 | $40,000 | +8.1% | 10,120 | -7.3% | 0.00% | – |
Q3 2021 | $37,000 | -11.9% | 10,920 | 0.0% | 0.00% | – |
Q2 2021 | $42,000 | -54.3% | 10,920 | -54.5% | 0.00% | – |
Q1 2021 | $92,000 | -7.1% | 23,981 | +10.2% | 0.00% | – |
Q4 2020 | $99,000 | -89.6% | 21,761 | -61.2% | 0.00% | -100.0% |
Q3 2020 | $948,000 | +989.7% | 56,104 | +619.3% | 0.00% | – |
Q2 2020 | $87,000 | +117.5% | 7,800 | -8.2% | 0.00% | – |
Q1 2020 | $40,000 | – | 8,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
Ergoteles LLC | 124,329 | $472,000 | 0.01% |
CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |